Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)

You may be eligible if

• MAIN ELIGIBILITY CRITERIA
• Histologically proven metastatic adenocarcinoma of colon or rectum
• Documented inoperable disease (i.e., not suitable for complete carcinological surgical resection)
• Measurable lesion as assessed by CT scan or MRI in at least one dimension (longest diameter to be recorded) ≥ 20 mm with conventional CT scan or ≥ 10 mm with spiral CT scan
• No previous therapy for metastatic disease
• No history or evidence upon physical examination of CNS disease (e.g., non-irradiated CNS metastasis, seizure not controlled with standard medical therapy, or history of stroke) unless adequately treated
• No exclusive bone metastasis
• ECOG performance status 0-2
• WBC ≥ 1,500/mm\^3
• Platelets ≥ 100,000/mm\^3
• Hemoglobin \> 9 g/dL (may be transfused to maintain or exceed this level)
• Proteinuria \< 2+ by dipstick OR ≤ 1 g of protein on 24-hr urine collection
• Bilirubin \< 1.5 times ULN
• Alkaline phosphatase \< 3 times ULN
• No peripheral sensory neuropathy
• Negative pregnancy test
• Fertile patients must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly, or surgically sterilization)
• No peripheral neuropathy ≥ grade 1
• No clinically significant (i.e. active) cardiovascular disease
• No evidence of bleeding diathesis or coagulopathy
• No serious, non-healing wound, ulcer, or bone fracture
• No significant ophthalmologic abnormality
• More than 28 days since prior major surgical procedure or open biopsy